RxDoctor Payments Data

April Treas, MD

Internal Medicine · Greenville, SCNPI 1174549455

Payments from drug & device makers

$7,150in general payments, 2019–2025

Across 419 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$968
  • Lilly USA, LLC$665
  • Novo Nordisk$609
  • Pfizer$576
  • AbbVie$556
  • Bayer$395
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$7,08599%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,150 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$174,110
Medicare patients
268
Services billed
2,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$112,795
MounjaroTirzepatide59$94,655
EliquisApixaban54$63,568
JardianceEmpagliflozin36$62,378
FarxigaDapagliflozin Propanediol20$31,710
TrulicityDulaglutide20$27,597
Tresiba Flextouch U-200Insulin Degludec13$23,201
KerendiaFinerenone13$19,440
XareltoRivaroxaban13$14,377
SynthroidLevothyroxine Sodium53$5,754
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,608
BelsomraSuvorexant13$5,560
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,909
Potassium Chloride54$4,423
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen114$3,410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$665$122,25379 claims
Novo NordiskOzempic$609$112,79588 claims
PfizerEliquis$576$63,56854 claims
Boehringer IngelheimJardiance$335$62,37836 claims
AstraZenecaFarxiga$968$31,71020 claims
BayerKerendia$395$19,44013 claims
Johnson & JohnsonXarelto$64$14,37713 claims
AbbVieSynthroid$556$5,75453 claims
GSKAnoro Ellipta$376$5,60812 claims
MerckBelsomra$78$5,56013 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$12$3,097288 claims
ANI Pharmaceuticals, Inc.Valsartan$28$2,942114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →